Global Information
회사소개 | 문의 | 위시리스트

세계의 약물 전달 시장 예측(-2023년) : 경구, 주사, 국소, 경안, 경폐, 경비, 경점막, 이식형 약물 전달

Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting - Global Forecast to 2023

리서치사 MarketsandMarkets
발행일 2019년 03월 상품 코드 344812
페이지 정보 영문 290 Pages
가격
US $ 5,650 ₩ 6,737,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,929,000 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,718,000 PDF by E-mail (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,924,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 약물 전달 시장 예측(-2023년) : 경구, 주사, 국소, 경안, 경폐, 경비, 경점막, 이식형 약물 전달 Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting - Global Forecast to 2023
발행일 : 2019년 03월 페이지 정보 : 영문 290 Pages

약물 전달 시장은 2018년 1조 2,444억 달러에서 2023년까지 1조 6,947억 달러에 달할 것으로 예측됩니다. 2018-2023년간 연평균 복합 성장률(CAGR) 6.4%의 성장이 예측됩니다.

세계의 약물 전달(Pharmaceutical Drug Delivery) 시장에 대해 조사 분석했으며, 시장 개요, 산업 동향, 부문별 시장 분석, 경쟁 구도, 주요 기업 등에 대한 체계적인 정보를 제공합니다.

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

  • 약물 전달 기술 : 시장 개요
  • 약물 전달 기술 시장 : 투여경로별
  • 약물 전달 기술 시장 : 이용시설별
  • 약물 전달 기술 시장 점유율 : 적응증 및 지역별
  • 약물 전달 기술 시장 : 지역별 성장 기회

제5장 시장 개요

  • 서론
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 해결해야 할 과제

제6장 약물 전달 기술 시장 : 투여경로별

  • 서론
  • 경구
  • 주사
  • 국소
  • 경안
  • 경폐
  • 경비
  • 경점막
  • 이식

제7장 약물 전달 기술 시장 : 이용시설별

  • 서론
  • 병원
  • 외래수술센터(ASC)/클리닉
  • 가정간호
  • 진단센터
  • 기타

제8장 약물 전달 기술 시장 : 적응증별

  • 서론
  • 감염증
  • 심혈관 질환
  • 당뇨병
  • 호흡기 질환
  • 중추신경계 질환
  • 자가면역질환
  • 기타

제9장 약물 전달 기술 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 기타

제10장 경쟁 구도

  • 개요
  • 시장 기업 순위
  • 경쟁 시나리오
  • 경쟁 리더십 매핑
  • 경쟁 구도와 동향

제11장 기업 개요

  • JOHNSON & JOHNSON SERVICES, INC.
  • NOVARTIS AG
  • F. HOFFMANN-LA ROCHE LTD.
  • PFIZER, INC.
  • BAYER AG
  • ANTARES PHARMA, INC.
  • BECTON, DICKINSON AND COMPANY
  • GLAXOSMITHKLINE PLC
  • 3M
  • MERCK & CO., INC.
  • SANOFI

제12장 부록

LSH 19.03.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

LIST OF TABLES

  • TABLE 1: INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2017)
  • TABLE 2: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 3: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 4: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 5: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 6: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 7: CAPSULES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 8: POWDERS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 9: PILLS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 10: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 11: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 12: ORAL SYRUPS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 13: ORAL SOLUTIONS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 14: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 15: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 16: ORAL GELS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 17: ORAL EMULSIONS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 18: ELIXIRS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 19: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 20: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 21: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 22: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 23: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2023 (USD BILLION)
  • TABLE 24: GLASS SYRINGES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 25: PLASTIC SYRINGES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 26: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2023 (USD BILLION)
  • TABLE 27: FILLABLE SYRINGES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 28: PREFILLED SYRINGES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 29: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2023 (USD BILLION)
  • TABLE 30: REUSABLE SYRINGES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 31: DISPOSABLE SYRINGES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 32: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 33: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 34: NEEDLE-FREE INJECTORS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 35: AUTOINJECTORS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 36: COMMERCIALLY AVAILABLE KEY PEN INJECTORS
  • TABLE 37: PEN INJECTORS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 38: WEARABLE INJECTORS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 39: OTHER INJECTOR DEVICES MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 40: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 41: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 42: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 43: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 44: TOPICAL SOLUTIONS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 45: TOPICAL SUSPENSIONS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 46: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 47: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 48: TOPICAL CREAMS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 49: TOPICAL GELS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 50: TOPICAL OINTMENTS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 51: TOPICAL PASTES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 52: TOPICAL LOTIONS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 53: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 54: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 55: TOPICAL SUPPOSITORIES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 56: TOPICAL POWDERS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 57: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 58: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 59: TRANSDERMAL PATCHES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 60: TRANSDERMAL GELS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 61: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 62: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 63: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 64: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 65: COMMERCIALLY AVAILABLE EYE DROPS
  • TABLE 66: EYE DROPS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 67: LIQUID SPRAYS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 68: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 69: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 70: OCULAR GELS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 71: EYE OINTMENTS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 72: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 73: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 74: DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 75: OCULAR INSERTS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 76: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 77: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 78: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 79: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR METERED-DOSE INHALERS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 80: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR DRY POWDER INHALERS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 81: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 82: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 83: JET NEBULIZERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 84: ULTRASONIC NEBULIZERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 85: SOFT MIST NEBULIZERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 86: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 87: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 88: NASAL DROPS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 89: NASAL SPRAYS MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 90: NASAL POWDERS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 91: NASAL GELS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 92: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 93: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 94: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 95: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 96: BUCCAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 97: SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 98: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 99: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 100: RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 101: VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 102: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 103: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 104: ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 105: PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 106: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 107: DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 108: DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 109: DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 110: DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 111: DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 112: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2023 (USD BILLION)
  • TABLE 113: DRUG DELIVERY TECHNOLOGY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 114: DRUG DELIVERY TECHNOLOGY MARKET FOR CANCER, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 115: DRUG DELIVERY TECHNOLOGY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 116: DRUG DELIVERY TECHNOLOGY MARKET FOR DIABETES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 117: DRUG DELIVERY TECHNOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 118: DRUG DELIVERY TECHNOLOGY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 119: DRUG DELIVERY TECHNOLOGY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 120: DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 121: DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 122: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 123: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 124: NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 125: NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 126: NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 127: NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 128: NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 129: NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2023 (USD BILLION)
  • TABLE 130: NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2023 (USD BILLION)
  • TABLE 131: NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2023 (USD BILLION)
  • TABLE 132: NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 133: NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 134: NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 135: NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 136: NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 137: NORTH AMERICA: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 138: NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 139: NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 140: NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 141: NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 142: NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 143: NORTH AMERICA: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 144: NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 145: NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 146: NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 147: NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 148: NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 149: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2023 (USD BILLION)
  • TABLE 150: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 151: US: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 152: US: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 153: CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 154: CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 155: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 156: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 157: EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 158: EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 159: EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 160: EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 161: EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 162: EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2023 (USD BILLION)
  • TABLE 163: EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2023 (USD BILLION)
  • TABLE 164: EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2023 (USD BILLION)
  • TABLE 165: EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 166: EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 167: EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 168: EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 169: EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 170: EUROPE: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 171: EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 172: EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 173: EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 174: EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 175: EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 176: EUROPE: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 177: EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 178: EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 179: EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 180: EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 181: EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 182: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2023 (USD BILLION)
  • TABLE 183: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 184: GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 185: GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 186: FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 187: FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 188: UK: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 189: UK: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 190: ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 191: ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 192: APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY, 2016-2023 (USD BILLION)
  • TABLE 193: APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 194: APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 195: APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 196: APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 197: APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 198: APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 199: APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2023 (USD BILLION)
  • TABLE 200: APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2023 (USD BILLION)
  • TABLE 201: APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016-2023 (USD BILLION)
  • TABLE 202: APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 203: APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 204: APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 205: APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 206: APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 207: APAC: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 208: APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 209: APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 210: APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 211: APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 212: APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, 2016-2023 (USD MILLION)
  • TABLE 213: APAC: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 214: APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 215: APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 216: APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 217: APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 218: APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 219: APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2023 (USD BILLION)
  • TABLE 220: APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 221: JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 222: JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 223: CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 224: CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 225: INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 226: INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 227: ROAPAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD MILLION)
  • TABLE 228: ROA: DRUG DELIVERY TECHNOLOGY MARKET, BY END USER, 2016-2023 (USD BILLION)
  • TABLE 229: ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD BILLION)
  • TABLE 230: ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 231: ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 232: ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 233: ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 234: ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 235: ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016-2023 (USD BILLION)
  • TABLE 236: ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016-2023 (USD BILLION)
  • TABLE 237: ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, 2016-2023 (USD BILLION)
  • TABLE 238: ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 239: ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 240: ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD BILLION)
  • TABLE 241: ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 242: ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 243: ROW: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 244: ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 245: ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 246: ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 247: ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016-2023 (USD MILLION)
  • TABLE 248: ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 249: ROW: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 250: ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 251: ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 252: ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 253: ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 254: ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 255: ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016-2023 (USD BILLION)
  • TABLE 256: ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016-2023 (USD BILLION)
  • TABLE 257: DRUG DELIVERY TECHNOLOGY MARKET PLAYER RANKING, 2017
  • TABLE 258: PRODUCT LAUNCHES AND APPROVALS, 2016-2018
  • TABLE 259: COLLABORATIONS, AGREEMENTS, AND JOINT VENTURES, 2016-2018
  • TABLE 260: ACQUISITIONS, 2015-2018
  • TABLE 261: EXPANSIONS, 2015-2018

LIST OF FIGURES

  • FIGURE 1: DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION
  • FIGURE 2: DRUG DELIVERY TECHNOLOGY MARKET: RESEARCH METHODOLOGY
  • FIGURE 3: RESEARCH DESIGN
  • FIGURE 4: FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023 (USD BILLION)
  • FIGURE 9: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2018 VS. 2023 (USD BILLION)
  • FIGURE 10: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 11: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2018 VS. 2023 (USD BILLION)
  • FIGURE 12: GEOGRAPHICAL SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 13: INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 14: TOPICAL DRUG DELIVERY SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 15: HOSPITALS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 16: INFECTIOUS DISEASES APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018
  • FIGURE 17: CHINA IS EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 18: DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19: TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 20: HOME CARE SETTINGS TO WITNESS THE HIGHEST GROWTH IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2018 TO 2023
  • FIGURE 21: INFECTIOUS DISEASES SEGMENT WILL CONTINUE TO DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD
  • FIGURE 22: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
  • FIGURE 23: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
  • FIGURE 24: ASIA PACIFIC: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
  • FIGURE 25: ROW: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT
  • FIGURE 26: KEY DEVELOPMENTS IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2016 TO 2019
  • FIGURE 27: MNM DIVE-VENDOR COMPARISON MATRIX: DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 28: MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 29: JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
  • FIGURE 30: NOVARTIS AG: COMPANY SNAPSHOT (2017)
  • FIGURE 31: F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2017)
  • FIGURE 32: PFIZER, INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 33: BAYER AG: COMPANY SNAPSHOT (2017)
  • FIGURE 34: ANTARES PHARMA, INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 35: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017)
  • FIGURE 36: GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2017)
  • FIGURE 37: 3M: COMPANY SNAPSHOT (2017)
  • FIGURE 38: MERCK & CO., INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 39: SANOFI: COMPANY SNAPSHOT (2017)

"Rising prevalence for chronic diseases and growth in the biologics market are expected to drive the overall growth of the pharmaceutical drug delivery market."

The global pharmaceutical drug delivery market is projected to reach USD 1,694.7 billion by 2023 from USD 1,244.4 billion in 2018, at a CAGR of 6.4% during the forecast period. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. On the other hand, the risk of needlestick injuries and the increasing pricing pressure are expected to challenge market growth in the coming years.

"The home care settings segment is expected to grow at the highest CAGR during the forecast period."

Based on facility of use, the pharmaceutical drug delivery market is segmented hospitals, ambulatory surgical centers (ASCs)/clinics, diagnostic centers, home care settings, and other facilities of use. The home care settings segment is expected to grow at a higher CAGR during the forecast period. This can majorly be attributed to increasing use of various drug delivery devices such as injectables, nebulizers, and inhalers in home care settings.

"The conventional injection devices segment accounted for the largest share of the injectable drug delivery market in 2018."

Based on type, the injectable drug delivery technology is segmented into conventional injection devices, self-injection devices, and other devices. In 2018, conventional injection devices accounted for the largest share of the injectable drug delivery technology market. The large share of this segment can primarily be attributed to factors such as the low cost of devices and manufacturing, large molecular size of biologics administered through injectables, and the widespread popularity of conventional devices.

"North America to dominate the market during the forecast period."

In 2018, North America accounted for the largest share of the pharmaceutical drug delivery market. The large share of the North American market is due to factors such as the rising prevalence of chronic diseases such as cancer, respiratory allergies, and diabetes; growth in biologics in the pharmaceuticals market; and the presence of a large number of prominent players in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 (55%), Tier 2 (25%), and Tier 3 (20%)
  • By Designation: C-level (43%), D-level (32%), and Others (25%)
  • By Region: North America (38%), Europe (23%), Asia (29%), and RoW (10%)

List of Companies Profiled in the Report:

  • Johnson & Johnson, Inc. (US)
  • F. Hoffman-La Roche (Switzerland)
  • Merck & Co., Inc. (US)
  • Bayer AG (Germany)
  • Pfizer, Inc. (US)
  • Novartis AG (Switzerland)
  • 3M Company (US)
  • Becton, Dickinson and Company (US)
  • GlaxoSmithKline plc, (UK)
  • Sanofi (France)
  • Antares Pharma, Inc. (US).

Research Coverage:

This report provides a detailed picture of the global pharmaceutical drug delivery market. It aims at estimating the size and future growth potential of the market across different segments, such as route of administration, application, facility of use, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical drug delivery market and its subsegments. This report will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. DRUG DELIVERY TECHNOLOGY: MARKET OVERVIEW
  • 4.2. DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023(USD BILLION)
  • 4.3. DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2018-2023(USD BILLION)
  • 4.4. DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY APPLICATION AND REGION, 2018
  • 4.5. DRUG DELIVERY TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
  • 5.3. DRIVERS
    • 5.3.1. RISING PREVALENCE OF CHRONIC DISEASES
    • 5.3.2. GROWTH IN THE BIOLOGICS MARKET
    • 5.3.3. TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES
  • 5.4. RESTRAINTS
    • 5.4.1. RISK OF NEEDLESTICK INJURIES
  • 5.5. OPPORTUNITIES
    • 5.5.1. SELF-ADMINISTRATION AND HOME CARE
    • 5.5.2. RISING DEMAND FOR BIOSIMILARS
  • 5.6. CHALLENGES
    • 5.6.1. PRICING PRESSURE

6. DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. INTRODUCTION
  • 6.2. ORAL DRUG DELIVERY
    • 6.2.1. SOLID ORAL DRUGS
      • 6.2.1.1. Tablets
        • 6.2.1.1.1. Development of mini-tablets is a key trend in this market segment.
      • 6.2.1.2. Capsules
        • 6.2.1.2.1. Easy absorption of drugs and decreased irritation in the GI tract are driving the use of capsules
      • 6.2.1.3. Powders
        • 6.2.1.3.1. Powders are taken by patients who are unable to swallow oral dosage forms
      • 6.2.1.4. Pills
        • 6.2.1.4.1. Rising incidence of target ailments will propel the growth of the pills market
    • 6.2.2. LIQUID ORAL DRUGS
      • 6.2.2.1. Syrups
        • 6.2.2.1.1. Liquid syrups can be easily administered to patients with swallowing difficulties
      • 6.2.2.2. Solutions
        • 6.2.2.2.1. Solutions are generally preferred by geriatric and pediatric patients
    • 6.2.3. SEMI-SOLID ORAL DRUGS
      • 6.2.3.1. Gels
        • 6.2.3.1.1. Gels are used for controlled drug release
      • 6.2.3.2. Emulsions
        • 6.2.3.2.1. Microemulsions offer protection against oxidation and enzymatic hydrolysis
      • 6.2.3.3. Elixirs
        • 6.2.3.3.1. Elixirs are hydraulic in nature and contain sweet and flavored substances
  • 6.3. INJECTABLE DRUG DELIVERY
    • 6.3.1. CONVENTIONAL INJECTION DEVICES
      • 6.3.1.1. By material
        • 6.3.1.1.1. Glass
        • 6.3.1.1.1.1. Glass syringes are considered to be one of the most durable and safe materials to store biologic drugs
        • 6.3.1.1.2. Plastic
        • 6.3.1.1.2.1. Plastic syringes are reasonably priced as compared to their glass counterparts
      • 6.3.1.2. By product
        • 6.3.1.2.1. Fillable syringes
        • 6.3.1.2.1.1. Ease of use and variable dosing formulations of fillable syringes are the major factors driving market growth
        • 6.3.1.2.2. Prefilled syringes
        • 6.3.1.2.2.1. Prefilled syringes offer improved dose accuracy and increased patient convenience and safety
      • 6.3.1.3. By usability
        • 6.3.1.3.1. Reusable syringes
        • 6.3.1.3.1.1. Reusable syringes are easy to dismantle and clean
        • 6.3.1.3.2. Disposable syringes
        • 6.3.1.3.2.1. Disposable syringes are widely used in medical practices due to their low cost and convenience
    • 6.3.2. SELF-INJECTION DEVICES
      • 6.3.2.1. Needle-free injectors
        • 6.3.2.1.1. Needle-free injectors enable fast drug delivery and show better reproducibility as compared to invasive drug delivery systems
      • 6.3.2.2. Autoinjectors
        • 6.3.2.2.1. Autoinjectors provide improved patient satisfaction as compared to manual injections
      • 6.3.2.3. Pen injectors
        • 6.3.2.3.1. Pen injectors are generally used when medications have to be administered more than once a week
      • 6.3.2.4. Wearable injectors
        • 6.3.2.4.1. Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare are supporting market growth
    • 6.3.3. OTHER INJECTOR DEVICES
  • 6.4. TOPICAL DRUG DELIVERY
    • 6.4.1. LIQUID FORMULATIONS
      • 6.4.1.1. Solutions
        • 6.4.1.1.1. Solutions accounted for a larger share of the topical drug delivery technology market for liquid formulations in 2018
      • 6.4.1.2. Suspensions
        • 6.4.1.2.1. Factors such as higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market in the coming years
    • 6.4.2. SEMI-SOLID FORMULATIONS
      • 6.4.2.1. Creams
        • 6.4.2.1.1. Creams are either water-in-oil or oil-in-water emulsions
      • 6.4.2.2. Gels
        • 6.4.2.2.1. Factors such as faster drug release and greater patient acceptability to drive the market for topical gels
      • 6.4.2.3. Ointments
        • 6.4.2.3.1. Ointments are widely used in analgesic indications
      • 6.4.2.4. Pastes
        • 6.4.2.4.1. Topical pastes are widely used for the treatment and prevention of skin irritation
      • 6.4.2.5. Lotions
        • 6.4.2.5.1. Easy administration of lotions to drive their demand among end users
    • 6.4.3. SOLID FORMULATIONS
      • 6.4.3.1. Suppositories
        • 6.4.3.1.1. Suppositories require a suitable base that ensures the compatibility and stability of the drug
      • 6.4.3.2. Powders
        • 6.4.3.2.1. Powders have a very fine particle size that covers a large surface area per unit weight
    • 6.4.4. TRANSDERMAL PRODUCTS
      • 6.4.4.1. Transdermal patches
        • 6.4.4.1.1. Transdermal patches prevent the premature metabolization of the drug through the liver
      • 6.4.4.2. Transdermal gels
        • 6.4.4.2.1. Transdermal gels help in the faster release of drugs on the target site
  • 6.5. OCULAR DRUG DELIVERY
    • 6.5.1. LIQUID FORMULATIONS
      • 6.5.1.1. Eye drops
        • 6.5.1.1.1. Rising prevalence of cataracts and other eye diseases is driving market growth
      • 6.5.1.2. Liquid sprays
        • 6.5.1.2.1. Liquid sprays have helped in overcoming drawbacks associated with traditional eye drops
    • 6.5.2. SEMI-SOLID FORMULATIONS
      • 6.5.2.1. Gels
        • 6.5.2.1.1. High viscosity of drugs, prolonged drug release, and ease of drug administration are factors contributing to market growth
      • 6.5.2.2. Eye ointments
        • 6.5.2.2.1. Eye ointments are safe to use, and help in improving ocular contact time with the drug
    • 6.5.3. OCULAR DEVICES
      • 6.5.3.1. Drug-coated contact lenses
        • 6.5.3.1.1. Better eyesight offered by lenses & high compliance to drive the market for drug-coated contact lenses
      • 6.5.3.2. Ocular inserts
        • 6.5.3.2.1. Ocular inserts help in the sustained release of drugs in the eye
  • 6.6. PULMONARY DRUG DELIVERY
    • 6.6.1. METERED-DOSE INHALERS
      • 6.6.1.1. These inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
    • 6.6.2. DRY POWDER INHALERS
      • 6.6.2.1. DPI drug formulations are chemically more stable than their counterparts are
    • 6.6.3. NEBULIZERS
      • 6.6.3.1. Jet nebulizers
        • 6.6.3.1.1. Jet nebulizers account for the largest share of the nebulizers market
      • 6.6.3.2. Ultrasonic nebulizers
        • 6.6.3.2.1. Ultrasonic nebulizers are easy to use and comfortable to handle
      • 6.6.3.3. Soft mist nebulizers
        • 6.6.3.3.1. Soft Mist nebulizers are preferred for the treatment of severe COPD
  • 6.7. NASAL DRUG DELIVERY
    • 6.7.1. NASAL DROPS
      • 6.7.1.1. Nasal drops are considered more efficient than nasal sprays
    • 6.7.2. NASAL SPRAYS
      • 6.7.2.1. Nasal sprays help in relieving nasal congestion, runny nose, itchy nose, and sneezing
    • 6.7.3. NASAL POWDERS
      • 6.7.3.1. Absence of preservatives & superior stability of formulations are some of the advantages associated with nasal powders
    • 6.7.4. NASAL GELS
      • 6.7.4.1. Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients
  • 6.8. TRANSMUCOSAL DRUG DELIVERY
    • 6.8.1. ORAL FORMULATIONS
      • 6.8.1.1. Buccal drug delivery
        • 6.8.1.1.1. Buccal drug delivery system is suitable for local and systematic therapies
      • 6.8.1.2. Sublingual drug delivery
        • 6.8.1.2.1. The rate of drug absorption through the sublingual route is 3-10 times higher than the oral route
    • 6.8.2. OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
      • 6.8.2.1. Rectal transmucosal drug delivery
        • 6.8.2.1.1. The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature
      • 6.8.2.2. Vaginal transmucosal drug delivery
        • 6.8.2.2.1. The permeability of the drug is high through the vaginal route of administration
  • 6.9. IMPLANTABLE DRUG DELIVERY
    • 6.9.1. ACTIVE IMPLANTABLE DRUG DELIVERY
      • 6.9.1.1. Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionized radiation
    • 6.9.2. PASSIVE IMPLANTABLE DRUG DELIVERY
      • 6.9.2.1. Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants

7. DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE

  • 7.1. INTRODUCTION
  • 7.2. HOSPITALS
    • 7.2.1. HOSPITALS WILL CONTINUE TO DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD
  • 7.3. AMBULATORY SURGERY CENTERS/CLINICS
    • 7.3.1. INCREASING PREFERENCE FOR ASCS HAS RESULTED IN A SIGNIFICANT RISE IN DEMAND FOR DRUG DELIVERY TECHNOLOGIES
  • 7.4. HOME CARE SETTINGS
    • 7.4.1. HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • 7.5. DIAGNOSTIC CENTERS
    • 7.5.1. RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
  • 7.6. OTHER FACILITIES OF USE

8. DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. INFECTIOUS DISEASES
    • 8.2.1. HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH
  • 8.3. CANCER
    • 8.3.1. CANCER FORMS A KEY THERAPEUTIC APPLICATION SEGMENT FOR DRUG DELIVERY TECHNOLOGIES
  • 8.4. CARDIOVASCULAR DISEASES
    • 8.4.1. INCREASING PREVALENCE OF CVDS IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET
  • 8.5. DIABETES
    • 8.5.1. EMERGENCE OF NEW TECHNOLOGIES IS SUPPORTING MARKET GROWTH
  • 8.6. RESPIRATORY DISEASES
    • 8.6.1. HIGH PREVALENCE OF ASTHMA & COPD TO DRIVE THE ADOPTION OF DRUG DELIVERY TECHNOLOGIES
  • 8.7. CENTRAL NERVOUS SYSTEM DISORDERS
    • 8.7.1. ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS
  • 8.8. AUTOIMMUNE DISEASES
    • 8.8.1. AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • 8.9. OTHER APPLICATIONS
    • 8.9.1. OPHTHALMIC DISORDERS
    • 8.9.2. ENDOCRINE DISORDERS

9. DRUG DELIVERY TECHNOLOGY MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
      • 9.2.1.1. Rising prevalence of chronic diseases and strong presence of key market players - Major factors driving market growth in the US
    • 9.2.2. CANADA
      • 9.2.2.1. Government support for research and the rising prevalence of chronic diseases are the major factors driving market growth in Canada
  • 9.3. EUROPE
    • 9.3.1. GERMANY
      • 9.3.1.1. Growing focus of pharmaceutical companies on the development of various drug delivery products is expected to drive market growth in Germany
    • 9.3.2. FRANCE
      • 9.3.2.1. High insurance coverage coupled with the increasing prevalence of chronic diseases to drive market growth in France
    • 9.3.3. UK
      • 9.3.3.1. Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for drug delivery technologies in the UK
    • 9.3.4. REST OF EUROPE
  • 9.4. ASIA PACIFIC
    • 9.4.1. JAPAN
      • 9.4.1.1. Favorable government initiatives and increasing geriatric population will drive market growth in Japan
    • 9.4.2. CHINA
      • 9.4.2.1. China had the largest diabetic population in the world in 2017
    • 9.4.3. INDIA
      • 9.4.3.1. Favorable initiatives and high disease incidence will drive market growth in India
    • 9.4.4. REST OF ASIA PACIFIC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET PLAYER RANKING, 2017
  • 10.3. COMPETITIVE SCENARIO
  • 10.4. COMPETITIVE LEADERSHIP MAPPING (2017)
    • 10.4.1. VENDOR INCLUSION CRITERIA
    • 10.4.2. VISIONARY LEADERS
    • 10.4.3. INNOVATORS
    • 10.4.4. DYNAMIC DIFFERENTIATORS
    • 10.4.5. EMERGING COMPANIES
  • 10.5. COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2017)
    • 10.5.1. PROGRESSIVE COMPANIES
    • 10.5.2. STARTING BLOCKS
    • 10.5.3. RESPONSIVE COMPANIES
    • 10.5.4. DYNAMIC COMPANIES

11. COMPANY PROFILE (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1. JOHNSON & JOHNSON SERVICES, INC.
  • 11.2. NOVARTIS AG
  • 11.3. F. HOFFMANN-LA ROCHE LTD.
  • 11.4. PFIZER, INC.
  • 11.5. BAYER AG
  • 11.6. ANTARES PHARMA, INC.
  • 11.7. BECTON, DICKINSON AND COMPANY
  • 11.8. GLAXOSMITHKLINE PLC
  • 11.9. 3M
  • 11.10. MERCK & CO., INC.
  • 11.11. SANOFI

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. RELATED REPORTS
  • 12.5. AUTHOR DETAILS
Back to Top
전화 문의
F A Q